Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verve Therapeutics, Inc. - Common Stock (NQ:VERV)

11.13 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Verve Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CAE, Verve, and MongoDB and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
News headline image
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
REMINDER – Verve Therapeutics, Inc. Investor Alert: Robbins LLP Reminds Shareholders of the VERV Class Action Lawsuit
From Robbins LLP
Via Business Wire
News headline image
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) INVESTOR ALERT: Investors With Large Losses in Verve Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
VERVE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Verve Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Stockholder Notice: Robbins LLP Informs Stockholders of the Class Action Filed Against Verve Therapeutics, Inc.
From Robbins LLP
Via GlobeNewswire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Verve Therapeutics, Inc. – VERV
From Rosen Law Firm
Via Business Wire
News headline image
Verve Therapeutics Announces Pipeline Progress and Reports Second Quarter 2024 Financial Results
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Leadership Update
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics to Participate in Upcoming Investor Conferences
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
News headline image
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
From Schall Law
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Updates on its PCSK9 Program
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Verve Therapeutics
Via GlobeNewswire
News headline image
Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
From Verve Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.